---
layout: default
title: Activated Charcoal Aethusa Cynapium Antimony Potas
parent: 僅模型預測 (L5)
nav_order: 158
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Aethusa Cynapium Antimony Potas
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Combination (Activated Charcoal + 6 Components): Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This candidate is a multi-ingredient preparation comprising Activated Charcoal, Aethusa Cynapium, Antimony Potassium Tartrate, Claviceps Purpurea Sclerotium, Iron, Sulfur, and Turpentine Oil — a profile consistent with a traditional or homeopathic formulation.
The TxGNN model returned **no predicted indications** for this combination, and **no original indications, no US market authorizations, and no safety records** were identified in any queried data source.
As a result, this candidate cannot proceed through standard repurposing evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no regulatory record found |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only) — in this case, no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why This Evaluation Cannot Proceed

No mechanism of action data is available for this combination. The constituent components span activated charcoal (an adsorbent), plant-derived alkaloid sources (Aethusa Cynapium, Claviceps Purpurea Sclerotium), inorganic elements (Iron, Sulfur, Antimony Potassium Tartrate), and a volatile oil (Turpentine Oil). This profile is characteristic of a homeopathic or compounded traditional remedy rather than a single-entity drug suitable for knowledge-graph-based repurposing.

Because TxGNN operates on individual drug entities mapped to DrugBank IDs, and no DrugBank ID was resolved for this multi-component string, the model could not generate a repurposing prediction. Without a prediction, there is no target indication around which to build a clinical evidence review.

---

## Safety Considerations

Please refer to the package insert for safety information. Individual components carry specific safety concerns (e.g., Antimony Potassium Tartrate is a heavy-metal compound with a narrow therapeutic window; Turpentine Oil is an irritant), but no consolidated safety record for this combination was retrieved from any queried source.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The data infrastructure required for repurposing evaluation is entirely absent — no DrugBank mapping, no original indication, no TxGNN prediction, and no safety record. Proceeding without these foundations would produce unreliable conclusions.

**To move forward, the following is required:**

- **Clarify drug identity**: Determine whether this represents a single marketed product (e.g., a homeopathic preparation) and obtain its full product name and registration details.
- **Resolve DrugBank IDs per component**: Each active ingredient should be evaluated individually rather than as a combined string; map each to its respective DrugBank ID.
- **Re-run TxGNN per component**: Execute repurposing prediction separately for Activated Charcoal, Iron, Sulfur, and any pharmacologically tractable components.
- **Obtain MOA data**: Query DrugBank or ChEMBL for the mechanism of action of each resolvable component.
- **Source safety records**: If a product dossier exists (e.g., a homeopathic registration), retrieve the package insert to populate warnings and contraindications.
- **Reassess scope**: Consider whether a multi-ingredient homeopathic formulation falls within the intended scope of the repurposing pipeline; if not, flag for exclusion from the candidate set.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

